MedTrace Logo

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

NCT00498056 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-11-01

No results posted yet for this study

Summary

The development of a safe and effective vaccine is the best strategy for preventing the spread of HIV-1. The purpose of this study is to determine the safety and effectiveness of and immune responses to an HIV vaccine regimen in healthy adults at risk for HIV infection.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

VRC-HIVDNA016-00-VP

DNA vaccine administered intramuscularly

BIOLOGICAL

VRC-HIVADV014-00-VP

Adenovirus vaccine administered intramuscularly

BIOLOGICAL

VRC-HIVDNA016-00-VP placebo

DNA vaccine placebo administered intramuscularly

BIOLOGICAL

VRC-HIVADV014-00-VP placebo

Adenovirus vaccine placebo administered intramuscularly

Sponsors & Collaborators

  • Centers for Disease Control and Prevention

    collaborator FED

  • HIV Vaccine Trials Network

    collaborator NETWORK

  • International AIDS Vaccine Initiative

    collaborator NETWORK

  • US Military HIV Research Program

    collaborator NETWORK

  • Vaccine Research Center

    collaborator UNKNOWN

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Scott M. Hammer, MD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00498056 on ClinicalTrials.gov